176 related articles for article (PubMed ID: 23879408)
1. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics.
Israni AK; Riad SM; Leduc R; Oetting WS; Guan W; Schladt D; Matas AJ; Jacobson PA;
Transpl Int; 2013 Oct; 26(10):982-9. PubMed ID: 23879408
[TBL] [Abstract][Full Text] [Related]
2. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients.
Arreola-Guerra JM; Serrano M; Morales-Buenrostro LE; Vilatobá M; Alberú J
Ann Transplant; 2016 Feb; 21():105-14. PubMed ID: 26879833
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus Trough Level at the First Month May Predict Renal Transplantation Outcomes Among Living Chinese Kidney Transplant Patients: A Propensity Score-Matched Analysis.
Yin S; Song T; Jiang Y; Li X; Fan Y; Lin T
Ther Drug Monit; 2019 Jun; 41(3):308-316. PubMed ID: 31083041
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus trough levels higher than 6 ng/mL might not be required after a year in stable kidney transplant recipients.
Jung HY; Seo MY; Jeon Y; Huh KH; Park JB; Jung CW; Lee S; Han SY; Ro H; Yang J; Ahn C; Choi JY; Cho JH; Park SH; Kim YL; Kim CD
PLoS One; 2020; 15(7):e0235418. PubMed ID: 32614859
[TBL] [Abstract][Full Text] [Related]
6. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
Gathogo E; Harber M; Bhagani S; Levy J; Jones R; Hilton R; Davies G; Post FA;
Transplantation; 2016 Apr; 100(4):871-8. PubMed ID: 26413990
[TBL] [Abstract][Full Text] [Related]
7. Average Tacrolimus Trough Level in the First Month After Transplantation May Predict Acute Rejection.
Aktürk S; Erdoğmuş Ş; Kumru G; Elhan AH; Şengül Ş; Tüzüner A; Keven K
Transplant Proc; 2017 Apr; 49(3):430-435. PubMed ID: 28340806
[TBL] [Abstract][Full Text] [Related]
8. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients.
Arreola-Guerra JM; Alberú J; Chew-Wong A; Macias DM; Hernández-Rosales J; Zuñiga-Macías L; Delgadillo-Castañeda R; Ricalde-Ríos G; Haro-Alcalde F; Villafán-Bernal JR; Ramos-Medellín CL; Reyes-Acevedo R
Clin Transplant; 2019 Dec; 33(12):e13749. PubMed ID: 31691354
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
[TBL] [Abstract][Full Text] [Related]
10. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation.
Jung HY; Cho SY; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
J Korean Med Sci; 2019 Apr; 34(12):e103. PubMed ID: 30940998
[TBL] [Abstract][Full Text] [Related]
12. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation.
Gaynor JJ; Ciancio G; Guerra G; Sageshima J; Roth D; Goldstein MJ; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
Transpl Int; 2016 Feb; 29(2):216-26. PubMed ID: 26442829
[TBL] [Abstract][Full Text] [Related]
13. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus Intrapatient Variability on Graft Outcomes in Adherent Renal Transplantation Patients: A Cross-Sectional Study.
Nafar M; Keshtkari S; Ziaie S; Firouzan A; Borumandnia N; Dalili N; Poorrezagholi F; Samadian F; Samavat S
Iran J Kidney Dis; 2024 May; 18(3):187-194. PubMed ID: 38904339
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of chronic kidney disease after liver transplantation--experience from west China.
Shao ZY; Yan LN; Wang WT; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
World J Gastroenterol; 2012 Mar; 18(9):991-8. PubMed ID: 22408361
[TBL] [Abstract][Full Text] [Related]
16. Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation.
Nguyen TVA; Nguyen HD; Nguyen TLH; Le VT; Nguyen XK; Tran VT; Le DT; Ta BT
BMC Nephrol; 2023 May; 24(1):131. PubMed ID: 37158838
[TBL] [Abstract][Full Text] [Related]
17. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
[TBL] [Abstract][Full Text] [Related]
18. Higher Variability of Tacrolimus Trough Level Increases Risk of Acute Rejection in Kidney Transplant Recipients.
Huang CT; Shu KH; Ho HC; Wu MJ
Transplant Proc; 2016; 48(6):1978-80. PubMed ID: 27569931
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
[TBL] [Abstract][Full Text] [Related]
20. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.
Jacobson PA; Schladt D; Israni A; Oetting WS; Lin YC; Leduc R; Guan W; Lamba V; Matas AJ;
Transplantation; 2012 Mar; 93(6):624-31. PubMed ID: 22334041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
